Exploring Physical Exercise for the Regulation and Control of Metabolic Disorders in College Students.

Summary

This clinical trial objective is to evaluate the effect of an aerobic physical exercise program on reducing triglycerides, blood pressure, abdominal obesity, altered glucose levels, and the increase in HDL in college-level students at the University of Colima. It will try to answer whether aerobic physical exercise reduces metabolic disorders (altered blood pressure and glucose levels, abdominal obesity, and increased HDL). A simple randomized clinical trial will be conducted with a sample of 48 voluntary students from the University of Colima, divided into two groups of 24 people (Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax; and Experimental Group -B-, will undergo an aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload).

Researchers will compare the results of both groups to confirm the effectiveness of the planned aerobic physical exercise in reducing these risks.

Conditions

• Metabolic Disorders
• Abdominal Obesity
• Blood Pressure Disorders
• Hypertriglyceridemia
• Hyperglycemia
• HDL-Deficiency

Interventions

BEHAVIORAL

Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)

Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload

BEHAVIORAL

Control group: Continuous aerobic physical exercise

Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.

Sponsors & Collaborators

• Pedro Julián Flores Moreno

  collaborator UNKNOWN

• Nelson Enrique Ramos Cuevas

  collaborator UNKNOWN

• Universidad de Colima

  lead OTHER

Principal Investigators

• Nelson Enrique Ramos Cuevas, BC · Universidad de Colima

• Fabián Rojas Larios, PhD · Universidad de Colima

• Pedro Julián Flores, PhD · Universidad de Colima

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

25 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-09-30

Primary Completion

2024-11-30

Completion

2025-06-30

Countries

• Mexico

Study Locations